Health knowledge made personal
Join this community!
› Share page:
Search posts:

Binding Domains from Plasmodium vivax and Plasmodium falciparum Erythrocyte Binding Proteins

Posted Feb 27 2011 7:00pm

Description of Invention:
Despite considerable research efforts worldwide it has not been possible to design an effective vaccine against malaria. The present invention provides the basis for an effective vaccine against the blood state of malaria infections.

This invention relates to the identification of functional domains of Plasmodium proteins which play a role in erythrocyte binding and invasion. The inventors have identified the erythrocyte binding domains of the sialic acid binding protein (SABP) of P. falciparum and the Duffy antigen binding protein (DABP) of P. vivax. The erythrocyte binding domains can be used as vaccines to induce immune responses which block erythrocyte binding and invasion by P. falciparum and P. vivax merozoites.

Kim L Sim (NIAID)
Chetan Chitnis (NIAID)
Louis H Miller (NIAID)
David S Peterson (NIAID)
Xin-zhuan Su (NIAID)
Thomas E Wellems (NIAID)

Patent Status:
HHS, Reference No. E-133-1993/0
PCT, Application No. PCT/US94/10230 filed 07 Sep 1994
PCT, Application No. PCT/US96/09508 filed 07 Jun 1996

Infectious Diseases
Infectious Diseases - Vaccines
Rare Diseases

For Licensing Information Please Contact:
Admin. Licensing Spec-InfectDis
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-496-7057
Fax: 301-402-0220

Ref No: 1183

Updated: 02/2011

Post a comment
Write a comment:

Related Searches